Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods – 31 May 2023

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply, importation, advertising, and manufacturing of therapeutic goods within Australia, ensuring they are safe, of acceptable quality, and perform as represented. This Act was introduced to address the need for a comprehensive legislative framework governing the therapeutic goods industry, thereby protecting public health by ensuring that only safe and effective therapeutic goods are available to consumers. The Act empowers the Therapeutic Goods Administration (TGA) to license manufacturers and oversee the therapeutic goods market. The policy objective of the Act is to safeguard the health and safety of the Australian public by maintaining strict regulatory standards for therapeutic goods. This legislative measure was enacted by the Parliament of Australia, demonstrating the commitment to upholding high standards in the therapeutic goods sector. The publication of the list of manufacturers granted a licence for the manufacture of therapeutic goods is a procedural notification under Section 38 of the Therapeutic Goods Act 1989. This notification, issued by Scott Pearce, the Delegate of the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration, serves to inform the public and relevant stakeholders of the granted licences. The listed companies, including AUSTRALIA BIOTECHNOLOGY MANUFACTURING PTY LTD, DHL SUPPLY CHAIN AUSTRALIA PTY LIMITED, and SYMBIO LABORATORIES PTY LTD, have been granted specific licences to manufacture therapeutic goods, thereby complying with the regulatory requirements set forth by the TGA. This transparency aims to uphold the integrity of the therapeutic goods market and ensure that only authorised entities are permitted to manufacture these goods within Australia.

Scope and Application

The Therapeutic Goods Act 1989 applies to persons or entities involved in the manufacture, supply, or distribution of therapeutic goods within Australia. This includes pharmaceutical products, medical devices, and biologicals, and encompasses a broad range of activities from research and development through to marketing and sales. The Act applies to both domestic and international entities, ensuring that all therapeutic goods available in Australia meet safety, quality, and efficacy standards set by the Therapeutic Goods Administration (TGA). The geographic reach of the Act is national, governing the therapeutic goods market across all states and territories of Australia. However, certain therapeutic goods, such as those listed on the Register of Therapeutic Goods, may be exempt from some licensing requirements under specific conditions. The Act also allows for the creation of subordinate instruments that can extend or restrict its application, enabling the TGA to adapt to emerging issues and technologies in the therapeutic goods sector. Exclusions and thresholds are defined within the Act itself and through subsidiary legislation, providing a comprehensive regulatory framework for the therapeutic goods industry.

Key Provisions

The Therapeutic Goods Act 1989 outlines several key provisions related to the regulation of therapeutic goods, with Section 38 being particularly significant in the context of licensing for manufacturing. According to this section, the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration, is empowered to issue licences to manufacturers of therapeutic goods (s 38). The Act mandates that any entity seeking to manufacture such goods must obtain a licence, and the Secretary has the authority to grant or refuse this licence based on specified criteria (s 38(1)). The licence specifies the conditions under which the manufacturing activities can be carried out, including the types of goods that can be produced and the standards that must be met (s 38(2)). The obligations imposed by the Act on the licensed manufacturers are extensive and aim to ensure the safety, quality, and efficacy of the therapeutic goods produced. Manufacturers are required to maintain detailed records of their production processes, including raw materials, manufacturing procedures, and quality control measures (s 41(1)). They must also conduct regular audits and inspections of their facilities to ensure compliance with the stipulated standards (s 41(2)). Additionally, the Act mandates that manufacturers must report any adverse events related to the therapeutic goods they produce to the Therapeutic Goods Administration (s 42(1)). Failure to comply with the requirements set forth in the Therapeutic Goods Act 1989 can result in serious consequences for the manufacturers. Offences under the Act can include manufacturing therapeutic goods without a valid licence, failing to maintain proper records, or not reporting adverse events as required (s 43). The penalties for such breaches can be severe, with the Act providing for both criminal and civil sanctions. For instance, individuals and corporations can be subject to fines of up to $2,200,000 for serious offences, and in some cases, imprisonment for up to five years (s 43(1), 43(2)). Furthermore, the Act allows for the cancellation of a manufacturing licence if a breach is found, effectively shutting down the manufacturer's operations (s 43(3)). These stringent measures underscore the importance of adherence to the Act's provisions to protect public health and safety.